The company said Stephen Lovass ceased to serve as segment leader of the Medical and Fluid Solutions Segment on April 28, 2025. It reported in the Original Form 8-K that he would assist with the leadership transition and separate from the company on June 1, 2025.

1. 01

   The company said Stephen Lovass ceased to serve as segment leader of the Medical and Fluid Solutions Segment on April 28, 2025. It reported in the Original Form 8-K that he would assist with the leadership transition and separate from the company on June 1, 2025.

2. 02

   Nordson said it entered into a Separation Agreement and Release with Lovass. It said the release of claims he signed became effective on June 10, 2025. Payments and benefits are conditioned on his signing the release.

3. 03

   Nordson said Lovass is entitled to a pro-rata annual cash incentive for fiscal 2025 and a cash payment of $832,759, inclusive of severance and the value of 1 year(s) of COBRA coverage. It said outplacement services are capped at $10,000 and financial planning services at $5,000.

4. 04

   Nordson said stock options granted on or before December 1, 2022 will continue to vest on schedule and remain exercisable until the earlier of June 1, 2030 or the original expiration date. It said restricted shares and units will vest on a pro-rated basis. In exchange, Lovass is subject to 1-year post-employment non-competition and non-solicitation obligations, as well as assistance with the leadership transition.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.